Immuno-Oncology | Specialty

Expert Underscores Importance of AE Management in GU Cancers

May 10th 2018

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.

Sonpavde Navigates the Evolving Bladder Cancer Landscape

May 9th 2018

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

FDA Grants Frontline Atezolizumab Priority Review for NSCLC

May 7th 2018

The FDA has granted a priority review to a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

FDA Approval Sought for Frontline Pembrolizumab Combo in Squamous NSCLC

May 3rd 2018

A supplemental biologics license application has been submitted to the FDA for the use of pembrolizumab in combination with standard chemotherapy as a treatment for patients with metastatic squamous non–small cell lung cancer.

Manipulating the T-Cell Receptor Yields Promising Immunotherapies

May 1st 2018

Components of the T-cell receptor complex, which links antigen recognition with T-cell activity and effector function, are being exploited for several types of cancer immunotherapy.

Dr. Garon on Immunotherapy Combinations in NSCLC

April 30th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

FDA Grants Priority Review for Full Approval of Frontline Pembrolizumab Combo in NSCLC

April 30th 2018

The FDA has granted a priority review to a supplemental biologics license application for frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

Expert Details Immunotherapy Developments in Lung Cancer

April 27th 2018

Charles M. Rudin, MD, PhD, discusses ongoing developments with immunotherapy in patients with non–small cell lung cancer.

Durvalumab/Tremelimumab Misses Endpoint in Phase III NSCLC Study

April 24th 2018

Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.

HCC: Emerging Therapies

April 24th 2018

Use of Immunotherapy for HCC

April 24th 2018

Clinical Use of Regorafenib in mHCC

April 24th 2018

Treatment of Relapsed/Refractory mHCC

April 24th 2018

First-Line Therapy in Advanced HCC

April 24th 2018

When to Move to Systemic Therapy in HCC

April 24th 2018

HCC: Role of Radiotherapy and Measuring Response

April 24th 2018

When to Use Locoregional Therapies in HCC

April 24th 2018

HCC: Criteria for Resection and Adjuvant Therapy

April 24th 2018

Multidisciplinary Team Approach to Treating HCC

April 24th 2018

Methods for Staging HCC

April 24th 2018